Blog
RSS FeedPosted by Michael Wonder on 13 Mar 2019
Pharma urges politicians to stop no-deal Brexit in today’s vote
13 March 2019 - Pharma has urged politicians to reject a no-deal Brexit in today’s crunch vote, reiterating warnings that ...
Posted by Michael Wonder on 12 Mar 2019
Optimism on Orkambi in England as talks to resume
12 March 2019 - Scotland's deal puts pressure on NHS England and NICE. ...
Posted by Michael Wonder on 12 Mar 2019
NICE u-turn backs use of Darzalex combo for myeloma relapse
12 March 2019 - Myeloma patients in England are set to gain NHS access to a new second-line treatment combination ...
Posted by Michael Wonder on 11 Mar 2019
NICE nod for Almirall's Ilumetri, UCB's Cimzia
11 March 2019 - The NICE has recommended Almirall's Ilumetri and UCB's Cimzia as a treatment options for severe plaque ...
Posted by Michael Wonder on 11 Mar 2019
How a post-Brexit trade deal with the US could make life-saving drugs unaffordable for the NHS
10 March 2019 - The UK is going to be at a distinct disadvantage in this negotiation – desperate for a ...
Posted by Michael Wonder on 11 Mar 2019
Cystic fibrosis breakthrough: vital drug could be made available as early as next month
8 March 2019 - A wonder drug that could dramatically improve the lives of thousands of cystic fibrosis patients may be ...
Posted by Michael Wonder on 11 Mar 2019
NICE provisionally approves Almirall's Ilumetri (tildrakizumab), as a cost effective option for adults with moderate-to-severe plaque psoriasis
8 March 2019 - Final NICE approval is expected in April 2019. ...
Posted by Michael Wonder on 08 Mar 2019
Campaigners call for NHS access to Orkambi as MP inquiry gets underway
8 March 2019 - Patients and campaigners took to the streets in London yesterday demanding NHS access to Vertex’ cystic ...
Posted by Michael Wonder on 08 Mar 2019
High price of cystic fibrosis drug not political, firm's boss tells MPs
8 March 2019 - CEO of company that makes Orkambi denies being ‘political minion’ for Donald Trump. ...
Posted by Michael Wonder on 06 Mar 2019
In UK and Ireland, SMA patients demand reimbursement for Spinraza
6 March 2019 - A drug appraisal committee of Britain’s NICE met in Manchester, England, for the third and final ...
Posted by Michael Wonder on 06 Mar 2019
Firm in NHS row over cystic fibrosis drug paid almost no UK tax
6 March 2019 - European division of Vertex made loss while paying large sum to profitable US owner. ...
Posted by Michael Wonder on 06 Mar 2019
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
6 March 2019 - NICE has requested further evidence on Amgen’s Blincyto (blinatumomab) for the treatment of adults with acute ...
Posted by Michael Wonder on 05 Mar 2019
NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access
1 March 2019 - Pressure will be maintained on costs, despite VPAS price cap deal. ...
Posted by Michael Wonder on 05 Mar 2019
How to fix a problem like Orkambi? Solutions suggested ahead of showdown
5 March 2019 - Approaches used in France and Germany could help break deadlock. ...
Posted by Michael Wonder on 04 Mar 2019
Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry
4 March 2019 - Vertex’s long-running spat with NHS England has amounted to a legal inquiry scheduled to begin this Thursday, ...